B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In humans, a single-nucleotide polymorphism in the B-cell chronic lymphocytic leukemia/lymphoma-2 (Bcl-2) gene, rs956572, has been found to significantly modulate Bcl-2 protein expression in the brain.
|
29422088 |
2018 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our previous studies showed that oligonucleotide-treated LNCaP prostate cancer cells compensate for diminished expression of B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2), an apoptosis inhibitor, by suppressing the expression of caspase-3 (an apoptosis promoter) while enhancing that of serine/threonine protein kinase (AKT1) (another apoptosis inhibitor).
|
26546525 |
2016 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Specific cutaneous involvement by B-CLL was confirmed by the detection of t(14;18)(q32;q21) (BCL2-IGH) using FISH in neoplastic B cells within the skin infiltrates.
|
25171429 |
2015 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although there are conflicting data regarding prognostic implications of isolated MYC aberrancy in these non-BLs, the co-occurrence of MYC rearrangements and either the antiapoptotic gene B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) or the transcriptional repressor BCL6 leads to an entity termed double-hit B-cell lymphoma (DHL) (or triple-hit if all 3 abnormalities are observed) with a particularly poor prognosis and no established treatment paradigms.
|
25060588 |
2014 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Shortly after treatment, a sharp rise in B-cell chronic lymphocytic leukemia/lymphoma 2 (Bcl2) expression levels occurred.
|
22692727 |
2012 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is noteworthy that 150 nM cucurbitacin I effectively blocked STAT3 signaling and downstream survival targets, such as B-cell chronic lymphocytic leukemia/lymphoma 2 (Bcl-2) and Bcl-2-like 1 (Bcl-xL) expression and induced apoptosis in CD133-positive NSCLC cells.
|
21225866 |
2011 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, selective down-regulation of GLI1 by antisense oligodeoxynucleotides (GLI1-ASO) results in decreased BCL2 expression and cell survival, suggesting that GLI1 may regulate BCL2 and, thereby, modulate cell survival in B-CLL.
|
19074837 |
2008 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The BCL2-938AA genotype is associated with increased Bcl-2 expression and a novel unfavorable genetic marker in patients with B-CLL.
|
16960146 |
2007 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Exposure of B-CLL cells to honokiol resulted in up-regulation of Bcl2-associated protein (Bax) and down-regulation of the expression of the key survival protein myeloid-cell leukemia sequence 1 (Mcl-1), which is associated with response to treatment in B-CLL patients.
|
15802533 |
2005 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Decreased expression of B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) and myeloid cell leukemia sequence 1 (MCL1) proteins and increased staining of Annexin V-positive cells showed that inhibition of FGFR3 induces apoptosis.
|
15897243 |
2005 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, several Bcl-2 family genes are regulated during B-CLL spontaneous apoptosis and their relative levels may contribute to in vivo progression of the disease.
|
14975737 |
2004 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells.
|
15291360 |
2004 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia.
|
14510944 |
2003 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
All B-CLL cases were bcl-2 protein positive.
|
12584586 |
2002 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our previous work demonstrated that antisense oligonucleotides complementary to Bcl-2 mRNA sequences were able to reduce Bcl-2 protein expression in B-cell chronic lymphocytic leukaemia (B-CLL) cells.
|
12481899 |
2002 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia.
|
11472347 |
2001 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
This increased in vitro cytotoxicity demonstrates a proof of the concept that a combination of Bcl-2 antisense oligonucleotides with conventional chemotherapeutic drugs may elicit an enhanced therapeutic effect in B-CLL and should therefore be considered for further investigation in the form of a clinical trial.
|
11699414 |
2001 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia--the role of Bcl-2 family dysregulation.
|
10576505 |
1999 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore Bcl-2 antisense oligonucleotides might be useful in the treatment of B-CLL.
|
10583267 |
1999 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine.
|
9613987 |
1998 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53.
|
9459175 |
1997 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, exposure of cells from three patients with B-CLL to bFGF showed an upregulation of bcl-2 protein after 4-8 h. Our data demonstrate that bFGF upregulates the expression of bcl-2 in these cells, suggesting that this increase in bcl-2 expression may play a role in the delay of fludarabine-induced apoptosis.
|
9009090 |
1997 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Drug-induced apoptosis in B-CLL cells was inversely related to Bcl-2/Bax ratios.
|
9328155 |
1997 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The in vitro rescue from death induced by IL-8 is reflected by an increased expression of bcl-2 mRNA in B-CLL cases incubated in the presence of IL-8.
|
8639799 |
1996 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia.
|
8943893 |
1996 |